JP2021530464A5 - - Google Patents

Info

Publication number
JP2021530464A5
JP2021530464A5 JP2020573421A JP2020573421A JP2021530464A5 JP 2021530464 A5 JP2021530464 A5 JP 2021530464A5 JP 2020573421 A JP2020573421 A JP 2020573421A JP 2020573421 A JP2020573421 A JP 2020573421A JP 2021530464 A5 JP2021530464 A5 JP 2021530464A5
Authority
JP
Japan
Prior art keywords
independently selected
alkyl
alkylene
optionally substituted
haloalkyl
Prior art date
Application number
JP2020573421A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021530464A (ja
JP7565802B2 (ja
JPWO2020006229A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/039499 external-priority patent/WO2020006229A1/en
Publication of JP2021530464A publication Critical patent/JP2021530464A/ja
Publication of JPWO2020006229A5 publication Critical patent/JPWO2020006229A5/ja
Publication of JP2021530464A5 publication Critical patent/JP2021530464A5/ja
Priority to JP2024114813A priority Critical patent/JP7787250B2/ja
Application granted granted Critical
Publication of JP7565802B2 publication Critical patent/JP7565802B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020573421A 2018-06-27 2019-06-27 炎症抑制用化合物 Active JP7565802B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024114813A JP7787250B2 (ja) 2018-06-27 2024-07-18 炎症抑制用化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862690788P 2018-06-27 2018-06-27
US62/690,788 2018-06-27
PCT/US2019/039499 WO2020006229A1 (en) 2018-06-27 2019-06-27 Compounds for inhibition of inflammation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024114813A Division JP7787250B2 (ja) 2018-06-27 2024-07-18 炎症抑制用化合物

Publications (4)

Publication Number Publication Date
JP2021530464A JP2021530464A (ja) 2021-11-11
JPWO2020006229A5 JPWO2020006229A5 (https=) 2022-07-04
JP2021530464A5 true JP2021530464A5 (https=) 2022-07-04
JP7565802B2 JP7565802B2 (ja) 2024-10-11

Family

ID=68987150

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020573421A Active JP7565802B2 (ja) 2018-06-27 2019-06-27 炎症抑制用化合物
JP2024114813A Active JP7787250B2 (ja) 2018-06-27 2024-07-18 炎症抑制用化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024114813A Active JP7787250B2 (ja) 2018-06-27 2024-07-18 炎症抑制用化合物

Country Status (8)

Country Link
US (1) US20210267996A1 (https=)
EP (1) EP3813805A4 (https=)
JP (2) JP7565802B2 (https=)
CN (1) CN112512515B (https=)
AU (2) AU2019293232B2 (https=)
BR (1) BR112020025018A2 (https=)
CA (1) CA3103432A1 (https=)
WO (1) WO2020006229A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113189340A (zh) * 2020-01-14 2021-07-30 中国医学科学院基础医学研究所 细胞焦亡通路在细胞治疗中的用途
WO2021257880A1 (en) * 2020-06-18 2021-12-23 Spring Discovery, Inc. Use of aldh modulators or gasdermin d inhibitors for prevention and treatment of aging and aging-related disorders and for boosting an immune system
CN112011499B (zh) * 2020-09-10 2022-06-03 徐州医科大学 一种制备细胞外囊泡的方法及其应用
US11065214B1 (en) 2020-09-18 2021-07-20 Spring Discovery, Inc. Combination therapies with disulfiram
EP4112051A1 (en) * 2021-06-30 2023-01-04 Op2 Drugs Anethole trithione for the treatment of vasculitides
CN113462653B (zh) * 2021-07-05 2022-10-04 东北农业大学 抗猪Gasdermin D蛋白单克隆抗体、分泌该单克隆抗体杂交瘤细胞株及其应用
AU2022309856A1 (en) * 2021-07-15 2024-01-18 Genentech, Inc. Therapeutic compounds and methods
CN113577288A (zh) * 2021-09-15 2021-11-02 皖南医学院第一附属医院（皖南医学院弋矶山医院） Mst4相关物质在制备治疗脑出血后神经炎症反应的药物中的应用
CN115819548B (zh) * 2021-11-16 2023-09-01 北京美德泰康生物科技有限公司 一种检测炎症相关疾病的标志物和方法
CN115947691B (zh) * 2022-03-01 2024-08-16 四川大学 哒嗪砜类衍生物及其用途
LU501764B1 (en) * 2022-03-31 2023-10-02 Leibniz Inst Fuer Naturstoff Forschung Und Infektionsbiologie E V Hans Knoell Inst Hki Gasdermin e expression in human t cells as a marker for proinflammatory t cell functions
CN115429794B (zh) * 2022-09-16 2023-11-17 温州医科大学附属口腔医院 3-甲基吲哚二甲基氨基二硫代酸酯在制备防治牙周炎药物的用途
CN119285558A (zh) * 2023-07-10 2025-01-10 四川大学 一类新型gsdmd抑制剂及其制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870101A (en) * 1987-03-17 1989-09-26 Merrell Dow Pharmaceuticals Inc. Method of inhibiting interleukin-1 release
IL122892A0 (en) * 1998-01-11 1998-08-16 Yeda Res & Dev Pharmaceutical compositions comprising a thiocarbamate
US6548540B2 (en) * 1998-09-08 2003-04-15 Charlotte-Mecklenburg Hospital Authority Method of treating cancer using dithiocarbamate derivatives
NZ545724A (en) * 2003-03-18 2007-11-30 Protemix Corp Ltd Use of a copper chelator for preventing and/or treating cardiovascular disease and/or associated heart failure
EP2101567A4 (en) * 2007-01-18 2010-04-21 Univ Utah Res Found COMPOSITIONS AND METHODS FOR DETECTING, TREATING OR PREVENTING REDUCED STRESS
EP2214709A4 (en) * 2007-11-08 2011-05-11 Univ Utah Res Found USE OF ANGIOGENESIS ANTAGONISTS IN DISEASES WITH ANOMAL VENEER PREPARATION
US20100137247A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
US20100135983A1 (en) * 2008-12-02 2010-06-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-inflammatory compositions and methods
EP2734240B1 (en) * 2011-07-18 2018-03-21 University Of Kentucky Research Foundation Protection of cells from alu-rna-induced degenereation and inhibitors for protecting cells
GB201804514D0 (en) * 2018-03-21 2018-05-02 Ucl Business Plc Treatment of pyroptosis

Similar Documents

Publication Publication Date Title
JP2021530464A5 (https=)
ES2607604T3 (es) Moduladores del receptor CXCR4 de quimiocina y usos relacionados con los mismos
US11844801B2 (en) Oral compositions of MK2 pathway inhibitor for treatment of immune conditions
KR102586710B1 (ko) C5a 억제제로서의 5-5 융합 고리
JP2020193222A (ja) ピペリジニルインドール誘導体の新規な使用
US7419981B2 (en) Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
JP6903585B2 (ja) 補体関連疾患の治療のための組成物および治療方法
García-Álvarez et al. Beta-3 adrenergic agonists reduce pulmonary vascular resistance and improve right ventricular performance in a porcine model of chronic pulmonary hypertension
BRPI0406762A (pt) Derivados de n-(1-benzil-2-oxo-2-(1-piperazinil)etil)-1-piperidincarb oxamida e compostos relacionados como antagonistas de cgrp, para tratamento de dores de cabeça
TW201934552A (zh) 作為C5aR抑制劑之經二芳基取代之5,5-稠合環化合物
TW201927782A (zh) 作為C5aR抑制劑之經二芳基取代之6,5-稠合環化合物
JP2021507889A (ja) ピラゾロピペリジン誘導体の新規な使用
JP2019519586A5 (https=)
JP2014513136A5 (https=)
JP2016522831A (ja) 炎症を予防および治療するためのクリオピリン阻害剤
JPWO2020006229A5 (https=)
US20190314382A1 (en) Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases
US9546175B2 (en) Organic compounds
TW201922704A (zh) 作為免疫調節劑之氘化化合物
AU2022220863A1 (en) Small molecule activators of yap transcriptional activity for regenerative organ repair
JP2007277222A (ja) 抗炎症用医薬組成物
US10975059B2 (en) Small molecule BRD4 modulators for HIV epigenetic regulation
EP3554500A1 (en) Trpa1 antagonists for use in the treatment of atopic dermatitis
ES2991300T3 (es) Antagonistas de PTGDR-1 y/o PTGDR-2 para prevenir y/o tratar lupus eritematoso sistémico
WO2025037010A1 (en) Fused piperidinyl bicyclic and related compounds for use in the treatment of diseases